Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

5 treatments under study, led by Ganciclovir

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 2/3 (1)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00354120Phase 2/3Completed

Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant

NCT00917826Phase 2Terminated

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Showing all 2 trials

Research Network

Common Treatments

  • Ganciclovir1
  • Globulina Antilinfocitaria1
  • Alentuzumab1
  • Valganciclovir1
  • Arginine Butyrate1

Active Sponsors

  • Gruppo Italiano Trapianto di Midollo Osseo1
  • Boston University1
  • HemaQuest Pharmaceuticals Inc.1

Top Investigators

Related Conditions

  • Myelofibrosis1
  • Lymphoblastic Leukemia1
  • Chronic Myeloid Leukemia1
  • Acute Myeloblastic Leukemia1
  • Ebv Lymphomas1

Activity Timeline